Congestive heart failure, frequently known as heart failure, is the medical condition affecting the heart muscle’s pumping ability. Some medical conditions including narrowing of the heart’s arteries or high blood pressure eventually weakens the heart, making it stiff for filling and pumping efficiently. Certain heart failure symptoms are shortness in breath while exerting or when lying down, fatigue, weakness, swelling in feet, ankles, and legs, rapid and irregular heartbeat, reduction in ability for exercising, persistent cough and wheezing with white or pink blood tinged phlegm, raised at night urination, swelling in abdomen, rapid gain in the weight owing to fluid retention, loss of appetite, difficulty to concentrate, nausea, decreased alertness, coughing up foamy and pink mucus, and severe breath shortness. There are 4 kinds of heart failure, viz. right-sided heart failure, left-sided heart failure, diastolic heart failure along with systolic heart failure. Lifestyle changes could help to prevent heart failure through managing and reducing stress, maintaining healthy weight, consuming healthy food, being physically active and fit, controlling diabetes and blood pressure.
Global Congestive Heart Failure Drugs Market Drivers:-
Robust drugs pipeline under development is amongst the major factor expected to drive growth of the global congestive heart failure drugs market over the forecast period. For instance, the solution of furosemide injection (SCP-101) funded by the Johns Hopkins University along with SC Pharmaceuticals Inc. was within clinical trials of phase 2 in 2015, the injection is prescribed for heart failure treatment. Azosemide and Furosemide funded by Hyogo College of Medicine completed its clinical trial in phase 4, in 2016, the drugs are utilized for treating congestive heart failures. Tolvaptan funded by Otsuka pharmaceuticals Co., Ltd was in its clinical trial of phase 3 in 2016, the drug is prescribed for heart failure treatment in children.
New drug approvals from the U.S. Food and Drug Administration (FDA) is expected to drive the global congestive heart failure drugs market growth over the forecast period. In 2016, Ireland-based company Allergan’s product Byvalson was approved by the U.S. FDA, the drug is used to treat hypertension. In 2015, the U.S.-based company Amgen Inc.’s Corlanor (ivabradine) was approved by the U.S. FDA, the drug is used for the treatment of chronic heart failure. Moreover, rising geriatric populace, unhealthy lifestyle, along with rising awareness for chronic disorders treatment are the factors expected to fuel growth of the global congestive heart failure drugs market over the forecast.
Low diagnosis rate and awareness for this disease including hypertension are major reasons for heart failure, this in turn is expected to restrain in global congestive heart failure drugs market over the forecast period. As per the NCBI published study in 2013, just 49% patients having hypertension were aware of diagnosis within developed countries, while this percentage (i.e. 40.8%) was way lower in emerging economies.
Request for Analysis of COVID-19 Impact on Congestive Heart Failure Drugs Market – https://www.coherentmarketinsights.com/insight/request-pdf/1839
Global Congestive Heart Failure Drugs Market Regional Analysis:-
North America is expected to gain the largest share in the global congestive heart failure drugs market owing to novel product launches and acquisitions and mergers. For instance, the U.S.-based Amgen Inc., in 2015, acquired the Netherlands-based Dezima Pharma, for expanding its portfolio of cardiovascular drugs by including cholesterol lowering TA-8995 drug in its portfolio.
Moreover, Europe region is expected to register robust growth owing to new drug launches for treating chronic diseases that helps in preventing heart failures. For instance, the Novartis AG introduced an Entresto drug in the U.K., in 2016. Entresto is utilized for treating heart failure having least ejection fraction (amount of blood percentage leaving heart at every contraction), it is the inhibitor of angiotensin receptor-neprilysin. Furthermore, high cardiovascular diseases’ prevalence in Asia Pacific is expected to fuel the global congestive heart failure drugs market growth in this region. As per the Indian Council of Medical Research (ICMR) and the All India Institute of Medical Science (AIIMS) conducted study in 2016, younger population in India i.e. aged 30 years or below are more likely to develop cardiovascular diseases owing to alcohol consumption, tobacco consumption, and unhealthy lifestyle.
Global Congestive Heart Failure Drugs Market Key Players:-
Major players functioning in the global congestive heart failure drugs market are Amgen Inc., Astra Zeneca Plc., Novartis AG, Bayer AG, Glaxo Smith Kline, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Gilead Sciences Inc.
Reasons to Purchase this Report
• Current and future of global Congestive Heart Failure Drugs market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Buy This Full Premium Research Report: https://www.coherentmarketinsights.com/insight/buy-now/1839
“Limited Time Offer”
Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.
We also offer 15% FREE Report customization.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/1839
Global Congestive Heart Failure Drugs Market Taxonomy:-
Based on Drug:-
- Angiotensin 2 Receptor Blockers
- ACE Inhibitors
- Beta Blockers
- Aldosterone antagonists
Based on Distribution Channel:-
- Retail Pharmacies
- Online Pharmacies
Based on Region:-
- North America
- Latin America
- Asia Pacific
- Middle East
Table of Content
Global Congestive Heart Failure Drugs Market Research Report
Section 1: Global Congestive Heart Failure Drugs Industry Overview
Section 2: Global Economic Impact on Congestive Heart Failure Drugs Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Congestive Heart Failure Drugs Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Congestive Heart Failure Drugs Market Forecast
Other Exclusive Reports:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027